Introduction
Natural killer (NK) cells are lymphocytes that participate in innate immune responses to intracellular pathogens and neoplastic cells [1, 2] . NK cells do not productively rearrange T cell receptor or immunoglobulin genes, but do express several activating and inhibitory receptors that regulate their activation and function. NK cells can spontaneously lyse certain tumor cells and pathogen-infected cells in an antibody-independent process known as natural killing or NK activity. Furthermore, NK cells can lyse antibody-coated target cells in a process known as antibody-dependent cellular cytotoxicity (ADCC). Thus, in addition to contributing to innate immunity, NK cells can participate in the elimination of infected or transformed cells during the effector phase of adaptive immune responses [1, 2] .
The FccRIIIa (CD16) complex is an Fc receptor for IgG that is expressed on approximately 90 % of human NK cells [1, 2] . Ligation of CD16 causes rapid tyrosine phosphorylation of f chain family members as well as ZAP-70 and Syk, with downstream activation of multiple signaling pathways, including the phospholipase C-c/inositol-1,4,5-trisphosphate/diacylglycerol, PI3-K/ERK, and p38 MAPK pathways [3, 4] . Functional consequences of CD16-mediated stimulation of NK cells include triggering of ADCC, expression of activation antigens, and secretion of several cytokines and chemokines [1, 5] .
Monoclonal antibodies are standard components of current cancer therapy. The mechanisms by which monoclonal antibodies exert antitumor activity are complex and have not been completely defined. Nevertheless, there is compelling evidence that signals mediated through Fc receptors contribute to the antitumor effects of rituximab, trastuzumab, and cetuximab [6] [7] [8] . Therefore, it is rational to combine therapeutic monoclonal antibodies with other agents (such as immunostimulatory cytokines) that can enhance the function of Fc receptor-bearing effector cells, including NK cells. IL-18 is an immunostimulatory cytokine that regulates both innate and adaptive immune responses [9] . IL-18 has antitumor activity in animal models [10, 11] and can be safely given to patients with cancer [12, 13] . We have investigated the effects of IL-18 on Fc receptor-mediated functions of NK cells in preclinical in vitro and in vivo models.
Materials and methods

Human cells and cell lines
Blood samples were obtained from patients with lymphoma who had undergone high-dose chemotherapy and autologous stem cell transplantation. Procedures for stem cell collection, administration of high-dose therapy, and autologous stem cell transplantation were as previously described [14] . Blood samples were also obtained from patients with advanced cancer enrolled on a clinical trial of recombinant human IL-18 [13] . These studies were approved by the Institutional Review Board at Indiana University Medical Center, and written informed consent was obtained from each subject prior to collection of blood samples. 
Immunophenotypic analysis
PBMCs and enriched NK cells were stained directly with fluorochrome-conjugated monoclonal antibodies, washed, fixed in 1 % formaldehyde, and analyzed by flow cytometry as previously described [15] using an FACScan or FACScalibur instrument from Becton-Dickinson (San Diego, CA, USA). During analysis, forward and sidescattering properties were used to create a lymphocyte gate. Thresholds for discriminating levels of staining above background were established by analysis of cells stained with fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, and allophycocyanin (APC)-conjugated control monoclonal antibodies. Arbitrary mean fluorescence intensity (MFI) units were calculated by dividing the geometric mean fluorescence of CD16 or CD32 staining on CD56 positive cells expressing these antigens at levels above background staining with control monoclonal antibodies by the geometric mean fluorescence of CD56 positive cells that did not express these antigens at levels above background staining.
For cancer patients treated with recombinant human IL-18, the absolute number of NK cells expressing CD16 was calculated by multiplying the absolute total lymphocyte count (determined by automated complete blood count with white cell differential) by the percentage of CD16 ? CD56 ? CD3-negative cells (determined by flow cytometry).
Analysis of IFN-c mRNA and protein levels PBMCs and enriched NK cells were incubated overnight at 37°C in medium alone or medium containing IL-12, IL-18, or both cytokines as indicated and then plated at 100,000 or 200,000 cells per well in 96-well microtiter plates. After overnight incubation at 37°C in wells containing medium alone or medium with cytokines as indicated, IFN-c protein levels were measured using specific ELISA kit according to the manufacturer's (R & D Systems, Minneapolis, MN) instructions. IFN-c mRNA levels were measured by quantitative PCR as previously described [16] . For Fc receptor stimulation assays, wells of microplates were pretreated with medium alone or medium containing 100 lg/mL of human IgG, incubated overnight at 4°C, and then washed with ice-cold PBS before adding cells. For some experiments, chemical inhibitors or F(ab 0 )2 fragments of CD16 monoclonal antibodies were added during the final overnight incubation with cytokines and/or immobilized IgG.
Cytotoxicity assays
Enriched NK cells were incubated overnight at 37°C in medium with or without 100 ng/mL IL-18 or 10 U/mL IL-12 and then incubated in 96-well microtiter plates together with Raji cells that had been untreated or pretreated for 30 min with rituximab 1 lg/mL. After coculture of NK cells and Raji cells for 4 h at 37°C, ADCC was measured using the CytoTox 96 kit from Promega (Madison, WI). For some experiments, neutralizing goat anti-human-IFN-c antibodies were added during overnight incubation of NK cells with IL-18 and during the 4 h ADCC assay.
Human lymphoma xenograft model in vivo
All animal experiments were approved by the Institutional Animal Care and Use Committee at GlaxoSmithKline. Sixto eight-week-old immunodeficient outbred female mice (SCID on ICR background) were obtained from Charles River USA. Preparation of tumor donor animals consisted of injecting Ramos lymphoma cells (5 9 10 6 cells/mouse) from tissue culture to the flank of donor mice in a separate experiment prior to the therapeutic study. Ramos tumors from donor mice were harvested and passed through a sterile sieve to generate tumor cell homogenate. The tumor homogenate was diluted 1:8 in sterile PBS and immediately injected in the left flank of therapeutic study recipient mice. Tumor homogenate recipients were randomized into therapeutic groups (n = 6/group) when tumors reached mean volume 100 mm 3 . Daily injections of recombinant murine IL-18 (GlaxoSmithKline) at 4 mg/kg were administered subcutaneously (s.c.), and rituximab was dosed at 2, 1, and 0.5 mg/kg intravenously (i.v.) twice a week. Tumor diameters were measured using standard manual calipers, and the volumes were calculated using the following formula: V (volume) = 0.5 9 [length 9 (width) 2 ]. Complete regression (CR) of tumors was defined as non-palpable or \10 mm 3 tumors. Percent of tumor growth inhibition was calculated at 19 days of the study (prior to euthanization of control tumors due to ethical reasons) using the following formula: 100
, where Ve19 indicates the mean tumor volume in treatment group on day 19, Ve0 the mean tumor volume in treatment group on day 0 of therapy, Vc19 the mean tumor volume in control group on day 19, and Vc0 the mean tumor volume in control group on day 0 of therapy.
Statistical analysis
The lower limit of detection for the IFN-c ELISA is 8 pg/mL. For data analysis, samples with IFN-c levels\8 pg/mL were assigned a value of 8 pg/mL. Means, SE, t tests, Wilcoxon tests were calculated using PASW Statistics 17.0 software (SPSS Inc., Chicago, IL, USA). All in vivo experiments were graphed and analyzed using GraphPad Prism software. Twoway ANOVA followed by Bonferronni post-test was used to determine statistical significance between therapeutic groups in data that included two variables (time and tumor volume in the line graphs). Data packages with one variable (tumor volume) were evaluated by one-way ANOVA followed by Bonferroni post-test (comparison among[2 groups in the bar graphs).
Results
IL-18 augments IFN-c production by human NK cells stimulated with immobilized IgG
Significant amounts of IFN-c were secreted by enriched human NK cells cultured in the presence of immobilized IgG, whereas IFN-c was not detected in supernatants of NK cells cultured in medium alone (Fig. 1a) . This result is compatible with previously published studies, showing that stimulation of NK cells via Fc receptors can promote IFN-c production [17, 18] . We found that IL-18 enhanced, in a dose-dependent manner, the production of IFN-c by NK cells exposed to immobilized IgG (Fig. 1a) . Levels of IFNc mRNA were not significantly increased in NK cells stimulated with IL-18 and immobilized IgG compared to NK cells stimulated with either agent alone (data not shown). Thus, post-transcriptional mechanisms appear to promote synergistic production of IFN-c by NK cells in response to IL-18 and immobilized IgG. In agreement with previous results [19, 20] , IL-18 alone stimulated only minor NK cell production of IFN-c (Fig. 1a) but acted synergistically with IL-12 to promote IFN-c production (data not shown). The highest concentration (100 ng/mL) of IL-18 used in our experiments is clinically relevant. Plasma concentrations of IL-18 in excess of 100 ng/mL can be achieved in cancer patients after administration of recombinant human IL-18 in doses that are associated with acceptable toxicity and significant biological activity [12, 13] .
Production of IFN-c in vivo is deficient in lymphoma patients treated with IL-12 after autologous stem cell transplantation [21] . A selective and profound deficiency of STAT4 in post-transplant patient PBMCs appears to be the major cause of defective IFN-c production in this setting [16, 20] . STAT4 is not known to participate in the signaling pathways required for IFN-c production after ligation of CD16 on NK cells [3, 22] . We therefore tested the effects of immobilized IgG on IFN-c production by posttransplant PBMCs. Levels of IFN-c did not differ significantly in supernatants of post-transplant versus control PBMCs after incubation in the presence of immobilized IgG (P = 0.161; data not shown). Moreover, IFN-c production in response to IL-12 plus immobilized IgG was not significantly different (P = 0.974) comparing post-transplant patient PBMCs (819 ± 356 pg/mL; n = 4) to control PBMCs (828 ± 105 pg/mL; n = 5). As expected [20] , IL-18 also synergistically enhanced IFN-c production by posttransplant patient PBMCs stimulated with IL-12 (data not shown). Thus, stimulation with IL-18 or by ligation of CD16 can enhance IL-12-induced IFN-c production by PBMCs obtained from lymphoma patients after autologous stem cell transplantation.
Role of CD16 in IFN-c production by NK cells stimulated with immobilized IgG
The CD16/f complex appears to be the major Fc receptor that triggers ADCC and cytokine production after exposure of NK cells to antibody-coated target cells [3, 23] . Nevertheless, some isoforms of FccRII (CD32) can participate in the activation of human NK cells [24, 25] . In the enriched NK cell preparations used for our experiments, CD16 was expressed at relatively high levels (MFI 54 ± 7; n = 10) by 88 ± 2 % of NK cells, whereas CD32 was expressed at low levels (MFI 6 ± 1) by only 3 ± 1 % of NK cells. Furthermore, IFN-c production by enriched NK cells cultured with immobilized IgG was reduced by 77 % in the presence of CD16 F(ab 0 )2 fragments (Fig. 1b) . CD16 F(ab 0 )2 fragments also had a consistent but less pronounced inhibitory effect on IFN-c production by NK cells stimulated with IL-18 and immobilized IgG (Fig. 1b) . In the absence of immobilized IgG, however, the addition of CD16 F(ab 0 )2 fragments augmented IFN-c production by NK cells stimulated with IL-18 (Fig. 1b) . These results are consistent with previous data showing that cross-linking of CD16 by monoclonal antibodies promotes IFN-c production by NK cells [26] . Our results indicate that ligation of Fig. 2) was nearly abolished by addition of 10 lM chemical inhibitors of PI-3 K (Wortmannin), ERK (U0126), and p38 MAPK (SB203580). Furthermore, IFN-c levels produced by enriched NK cells in response to IL-18 and immobilized IgG were reduced to undetectable levels in the presence of 10 lM chemical inhibitor of Syk (piceatannol; data not shown). As expected, NK cells stimulated with IL-18 alone produced very little IFN-c (Fig. 2) , and the levels of IFN-c secreted by IL-18-activated NK cells were not significantly different in the presence or absence of Wortmannin (P = 0.3041), U0126 (P = 0.3075), or SB203580 (P = 0.3075).
Effects of IL-18 on expression of Fc receptors by NK cells
It has been reported that CD16 expression is diminished on human NK cells stimulated in vitro with IL-18; the percentage of NK cells expressing CD16 decreased from >90 % before culture to approximately 60 % after 24-48 h of culture in the presence of IL-18 [27] . We did not find the percentage of NK cells expressing CD16 to be significantly different after in vitro culture for 2 or 5 days in medium containing IL-18 100 ng/mL compared to those cultured in medium alone (data not shown). However, the MFI of CD16 on NK cells cultured with IL-18 for 2 days was 24 ± 7 (mean ± SE) as compared to 41 ± 7 for NK cells cultured in medium alone (P = 0.0002). The MFI of CD16 on NK cells stimulated with IL-18 for 5 days was 12 ± 4 as compared to 22 ± 5 for NK cells cultured in medium alone (P = 0.0704). The IL-18-induced decrease in CD16 levels on NK cells was not associated with any impairment in CD16-mediated IFN-c production (Fig. 1a) or cytolytic activity (Fig. 3) .
We also examined the expression of CD16 on the NK cells of cancer patients who were given weekly intravenous infusions of recombinant human IL-18 for up to 24 consecutive weeks. At the time points that were evaluated (weeks 1-5 of study), the absolute number of CD16 ? NK cells was not significantly diminished in patients receiving recombinant human IL-18 ( Table 1 ). The MFI of CD16 expressed on NK cells was not assessed in this clinical trial.
However, if the level of CD16 on the surface of NK cells did indeed decline during IL-18 therapy, the magnitude of this change was not sufficient to cause a reduction in the number of CD16 ? NK cells detected in peripheral blood. Enriched human NK cells exhibited poor cytolytic activity against unsensitized Raji lymphoma cells, which are relatively resistant to natural killing. However, Raji cells sensitized with rituximab were efficiently killed by NK cells (Fig. 3) . ADCC mediated by NK cells against rituximabcoated lymphoma cells was significantly augmented by IL-18, whereas IL-18 by itself did not promote killing of unsensitized Raji cells (Fig. 3) . Lysis of rituximab-sensitized Raji cells by NK cells stimulated with IL-18 100 ng/mL was not significantly different than that by NK cells stimulated with IL-12 10 U/mL (data not shown). Flow cytometric analysis failed to detect expression of IL-18Ra or IL-18Rb on Raji cells. Furthermore, incubation of Raji cells for up to 48 h in the presence of IL-18 100 ng/ mL did not affect their viability (data not shown). Therefore, the enhanced killing of rituximab-sensitized Raji cells detected in our ADCC assays is due to effects of IL-18 on NK cells and is not due to direct effects of residual IL-18 on Raji cells. Furthermore, expression of CD20 was not increased on Raji cells cultured in vitro with IL-18 (data not shown). As noted above, human NK cells stimulated with IL-18 in vitro actually express diminished levels of CD16. Therefore, IL-18 does not enhance ADCC by augmenting interactions between CD16 on NK cells and its ligand (Fc region of rituximab) on sensitized Raji cells. Rather, IL-18 appears to costimulate CD16-mediated cytolytic activity in a fashion similar to its costimulation of CD16-mediated IFN-c production.
IL-18 and ligation of CD16 can synergistically augment IFN-c production by human NK cells (Fig. 1a) . IFN-c can mediate tumor regression by direct antiproliferative and/or pro-apoptotic effects on tumor cells and by stimulating antitumor responses by effector cells [28] . We therefore investigated the potential role of IFN-c in lysis of Raji cells by IL-18-activated NK cells. Incubation of Raji cells for up to 48 h in the presence of IFN-c 10 ng/mL did not affect their viability or expression of CD20 (data not shown). Moreover, neutralizing anti-IFN-c antibodies did not inhibit lysis of Raji cells by IL-18-activated NK cells (data not shown). Thus, we have no evidence that IFN-c participates in NK cell ADCC against rituximab-sensitized target cells in vitro.
IL-18 enhances the efficacy of rituximab treatment in a murine model of lymphoma
The in vivo antitumor effects of IL-18 in combination with rituximab were evaluated in human Ramos lymphoma xenograft model. IL-18 monotherapy at 4 mg/kg daily s.c., or rituximab monotherapy at doses 0.5, 1, and 2 mg/kg resulted in significant Ramos tumor inhibition as compared to the control (vehicle) group (Fig. 4a) . However, none of the monotherapy groups demonstrated significant number of complete regressions ( Fig. 4a ; Table 2 ). Addition of IL-18 to rituximab led to statistically significant enhancement of antitumor effects on Ramos lymphomas in all combination therapy groups when compared to the corresponding monotherapy dose groups (Fig. 4b) . Moreover, there was a remarkable improvement in complete regression rates with almost complete tumor elimination and 83 % (5/6) complete tumor regressions in the IL-18 and rituximab (2 mg/kg) dose group ( Fig. 4a; Table 2 ). No evidence of dose-related toxicity or weight loss was observed in any of the treatment groups throughout the study.
Discussion
Immunostimulatory cytokines have been shown to augment functional responses of NK cells activated through CD16 [5, 17, 18, 29] . Our results demonstrate that IL-18 can also potently costimulate NK cells activated by ligation of Fc receptors. IL-18 alone, even in concentrations as high as 100 ng/mL, did not induce lysis of unsensitized Raji cells and stimulated very low levels of IFN-c production. However, IL-18 strongly costimulated the CD16-mediated cytolytic activity and IFN-c production (Figs. 1a, 3) . Indeed, the levels of IFN-c secreted by NK cells stimulated with IgG and IL-18 were almost as high as those secreted by NK cells stimulated with IL-12 plus IL-18 (data not shown), a cytokine combination which has been shown to strongly costimulate IFN-c production by human and murine NK cells [19, 20] . The very high levels of IFN-c produced by lymphocytes stimulated with IL-12 plus IL-18 appear to be due to STAT4-dependent enhanced transcription of the IFN-c gene as well as p38-dependent stabilization of the IFN-c mRNA [30, 31] . The mechanisms Ten patients were given weekly intravenous infusions of recombinant human IL-18 at doses of 100 (4 patients), 1,000 (3 patients), or 2,000 (3 patients) lg/kg as previously described [13] . Blood samples were obtained prior to IL-18 infusions on weeks 1, 2, 4, and 5 of study, and the absolute number of CD16 ? NK cells was determined as described in Materials and Methods. Results shown are mean ± SE of data from 9 patients. One patient did not have a sample obtained at baseline (week 1) and has been excluded from the analysis by which IL-18 and immobilized IgG synergistically induce IFN-c production have not been fully elucidated. Nevertheless, quantitative PCR analysis of IFN-c mRNA levels indicates that post-transcriptional mechanisms are predominantly responsible for the synergistic production of IFN-c in response to IL-18 and immobilized IgG. Furthermore, our data support a role for p38 in this synergy, as the p38 inhibitor SB203580 virtually abolished IFN-c production by NK cells stimulated with IL-18 and immobilized IgG. IL-12 can induce p38-dependent IFN-c production by Stat4 -/-murine lymphocytes [32] . Moreover, we have previously shown that IL-12 plus IL-18 can synergistically Fig. 4 IL-18 enhances the efficacy of rituximab in SCID mice with human B cell lymphoma xenografts. SCID-ICR mice (n = 6/group) bearing subcutaneous human Ramos lymphoma xenografts were treated with IL-18 or rituximab monotherapy, or with combination of both agents. a Tumor growth in combination therapy groups was significantly suppressed (*P \ 0.05, **P \ 0.01, ***P \ 0.001, two-way ANOVA followed by Bonferroni post-test) as compared to the rituximab monotherapy groups. Moreover, the number of complete tumor regressions was significantly increased in combination therapy groups as compared to rituximab (Table 2) or IL-18 monotherapy (0/6). Mice in the control group in some of the monotherapy groups (#) had to be euthanized due to ethical reasons before the study ended. b Tumor volumes on day 25 show statistically significant tumor growth suppression in all combination therapy groups as compared to their respective rituximab (*P \ 0.05, **P \ 0.01, t test) monotherapy groups and to the IL-18 monotherapy group (**P \ 0.01, one-way ANOVA followed by Bonferroni posttest) (Fig. 1b) . Thus, CD16 F(ab 0 )2 fragments appear to block binding of a stronger agonist (immobilized IgG) to CD16, while simultaneously acting as a weaker agonist by ligating CD16 to promote IFN-c production in concert with IL-18.
IFN-c did not appear to enhance the lysis of rituximabcoated lymphoma cells by human NK cells in vitro. This observation does not preclude the participation of IFN-c in NK cell-mediated antitumor immune responses in vivo. IFN-c can augment ADCC by monocyte/macrophages, enhance presentation of antigens by dendritic cells, and promote the differentiation of Th1 helper effector cells [28] . IFN-c also stimulates production of the CXC chemokines MIG (CXCL9) and IP-10 (CXCL-10), which can inhibit tumor angiogenesis and recruit CXCR3-bearing effector cells to tumor sites [33] . Therefore, IFN-c produced by NK cells activated in vivo by IL-18, and monoclonal antibodies could contribute to tumor regression during cancer immunotherapy.
One strategy to improve the efficacy of monoclonal antibody-based therapies for cancer is the administration of agents that can augment the antitumor activity of Fc receptor-bearing effector cells. Our results clearly show that IL-18 can enhance ADCC mediated by NK cells against rituximab-coated lymphoma cells in vitro. We have also found that IL-18 enhances the antitumor effects of rituximab in vivo in a SCID mouse model of human B cell lymphoma. By adding IL-18 to rituximab dosed at 2 mg/kg, we were able to achieve almost complete elimination of tumor growth as well as tumor regression in 83 % (5/6) of treated mice. The SCID mice used for our lymphoma xenograft model lack mature T and B cells but have normal NK cells and macrophages. Rituximab is a chimeric monoclonal antibody consisting of murine Fab portions that specifically recognize the human CD20 antigen and human IgG1 Fc portion that binds to Fc receptors on effector cells. Human CD20 monoclonal antibodies of IgG1 isotype can trigger the in vitro lysis of human lymphoma cells by murine NK cells and phagocytosis of human lymphoma cells by murine macrophages [34] . We did not directly examine the relative contributions of NK cells and macrophages to the in vivo antitumor effects of IL-18 and rituximab. Previous studies using SCID mouse models of lymphoma have found that murine NK cells mediate antitumor activity during rituximab-based therapy [35, 36] .
NK cells have also been implicated in the efficacy of IL-18-based immunotherapy against syngeneic tumors in immunocompetent mice [10, 37] . IL-18 therapy has been shown to activate NK cells in vivo, promote IFN-c production, and cause complete tumor regression in the MOPC-315 plasmacytoma tumor model [38] . In addition to innate effector cells, CD4 and CD8 T cells can participate in antitumor activity in syngeneic mouse tumor models [10, 37] . Thus, administration of IL-18 with monoclonal antibodies to lymphoma patients could enhance innate immune responses mediated by Fc receptor-bearing NK cells and monocytes as well as promote antigen-specific antitumor T cell responses. It is therefore rational to combine IL-18 with monoclonal antibodies in the treatment of cancer. A phase I clinical trial has provided proof-of-principle that therapy with IL-18 and rituximab is feasible in patients with relapsed or refractory lymphoma [39] . Further clinical trials test the efficacy of IL-18 plus monoclonal antibodies in the treatment of cancer are warranted.
